Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Post by elgin1on Jan 25, 2021 5:43pm
138 Views
Post# 32379203

@TOTALDESTRUCTION

@TOTALDESTRUCTION

Tc,

Not sure where your getting your info from. Orphan Drug status by Fda will be approved after another 23 patients for Hypoglycemic diabetics. That will be less than 2 years imo  .... not Type 1 Diabetes... that will take a few years with multicenter study and much larger patient pool.

They also have indications for Hemophilia and Thyroid and possibly a few others not mentioned yet.

There were 3 sets of warrants to be exercised . They will be done by end of the week. Weak hands are gone, some longterm shareholders from 5 cent placement cashed out . You can't blame them for waiting more than 10 years.

It's going to take a pharma collaboration that involves equity stake and this will be a double from here.  Conparabkes are valued at $1 Billion US with no clinical Fda trials . 


it does not matter what you say Totalcorruption because the share price will be determined by the market .... will be at much higher valuations.

Just hope you did not short it .

Elgin 

<< Previous
Bullboard Posts
Next >>